

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only, and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Beijing Chunlizhengda Medical Instruments Co., Ltd.\**



北京市春立正達醫療器械股份有限公司

**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***

*(A joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1858)**

## **INSIDE INFORMATION 2021 PRELIMINARY RESULTS ANNOUNCEMENT**

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.\* (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Please also refer to the overseas regulatory announcement of the Company dated 24 February 2022.

The major financial data for the year 2021 contained in this announcement is preliminary accounting data, which has not been audited by an accounting firm and is subject to the 2021 annual report of the Company. Investors are advised to pay attention to investment risks.

# I. MAJOR FINANCIAL DATA AND INDICATORS FOR THE YEAR 2021

Unit: RMB

Item	Reporting period	Corresponding period of last year	Increase/decrease (%)
Total revenue	1,081,056,855.25	937,686,185.19	15.29
Operating profit	356,584,907.82	330,095,515.42	8.02
Total profit	356,371,975.64	329,846,568.13	8.04
Net profit attributable to owners of the parent company	312,966,911.06	283,373,280.95	10.44
Net profit attributable to owners of the parent company after deducting non-recurring gains and losses	298,299,166.75	276,644,590.55	7.83
Basic earnings per share (RMB)	0.90	0.82	9.76
			Decreased by 4.78 percentage points
Weighted average returns on net assets	25.32%	30.10%	

Item	At the end of the reporting period	At the beginning of the reporting period	Increase/decrease (%)
Total assets	3,017,656,745.25	1,539,995,076.78	95.95
Equity attributable to owners of the parent company	2,459,683,560.75	1,079,588,357.46	127.84
Share capital	384,280,000.00	345,852,000.00	11.11
Net assets per share attributable to owners of the parent company (RMB)	6.40	3.12	105.13

Note: 1. The data as at the beginning of the reporting period is the same as the data statutorily disclosed as at the end of last year.

2. The financial data and indicators above are extracted from the data of the consolidated financial statements and are unaudited. The finalised results are subject to the 2021 annual report of the Company.

## II. EXPLANATION OF THE OPERATING RESULTS AND FINANCIAL STATUS

### (1) Operating conditions, financial conditions and major factors affecting operating results during the reporting period

During the reporting period, the Company achieved total revenue of RMB1,081,056,855.25, representing an increase of 15.29% as compared to the corresponding period of last year; operating profit of RMB356,584,907.82, representing an increase of 8.02% as compared to the corresponding period of last year; a total profit of RMB356,371,975.64, representing an increase of 8.04% as compared to the corresponding period of last year; net profit attributable to owners of the parent company of RMB312,966,911.06, representing an increase of 10.44% as compared to the corresponding period of last year; net profit attributable to owners of the parent company after deducting non-recurring gains and losses of RMB298,299,166.75, representing an increase of 7.83% as compared to the corresponding period of last year; and basic earnings per share of RMB0.90, representing an increase of 9.76% as compared to the corresponding period of last year.

As at the end of the reporting period, the total assets of the Company amounted to RMB3,017,656,745.25, representing an increase of 95.95% as compared to that as at the beginning of the reporting period; the equity attributable to owners of the parent company amounted to RMB2,459,683,560.75, representing an increase of 127.84% as compared to that as at the beginning of the reporting period; and the net assets per share attributable to owners of the parent company amounted to RMB6.40, representing an increase of 105.13% as compared to that as at the beginning of the reporting period.

In 2021, the Company overcame the impact of the COVID-19 epidemic and actively responded to the national centralized procurement policy for artificial joints. With such efforts, the Company managed to achieve the stable development of its principal business and a continued growth in overall performance. In order to enhance product competitiveness and expand brand influence, the Company continued to increase the investment in research and development and the marketing efforts, resulting in a lower increase in profit as compared to the increase in revenue during the reporting period.

### (2) The main reasons for the relevant items in the above table with a change percentage of over 30%

During the reporting period, the Company's total assets, the equity attributable to owners of the parent company, and the net assets per share attributable to owners of the parent company increased by over 30%, respectively, which was mainly due to the proceeds received by the Company from the listing on the Sci-Tech Innovation Board.

### III. RISK WARNING

The Company is not aware of any material uncertainties that will affect the accuracy of the content of this preliminary results announcement.

The major financial data for the year 2021 contained in this announcement is preliminary accounting data and have not been audited by an accounting firm and is subject to the audited 2021 annual report of the Company to be duly disclosed. Investors are reminded of the investment risks.

By order of the Board  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***  
**Shi Chunbao**  
*Chairman*

Beijing, the PRC, 24 February 2022

*As at the date of this announcement, the executive Directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.*

\* For identification purposes only